Alaunos Therapeutics, Inc.
(NASDAQ : ZIOP)

( )
ZIOP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.01%134.440.0%$887.68m
AMGNAmgen, Inc. 0.36%253.951.5%$855.01m
GILDGilead Sciences, Inc. 0.26%64.641.0%$546.26m
VRTXVertex Pharmaceuticals, Inc. 0.57%271.191.9%$490.50m
REGNRegeneron Pharmaceuticals, Inc. 0.16%684.502.6%$435.21m
ILMNIllumina, Inc. -0.41%242.583.3%$312.19m
NVAXNovavax, Inc. -0.15%47.0075.7%$258.06m
BIIBBiogen, Inc. 0.46%205.161.8%$233.78m
BNTXBioNTech SE 0.24%158.530.0%$211.49m
SNSSSunesis Pharmaceuticals, Inc. 0.00%2.100.7%$146.80m
EXASEXACT Sciences Corp. 0.96%50.3417.7%$129.43m
TECHBio-Techne Corp. 0.00%365.324.5%$100.31m
TXG10X Genomics, Inc. 0.00%47.350.0%$95.11m
BMRNBioMarin Pharmaceutical, Inc. 0.00%78.864.2%$94.54m
CRSPCRISPR Therapeutics AG 3.66%57.250.6%$83.34m

Company Profile

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.